Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Assets Average (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 15 years of Assets Average data on record, last reported at $30.1 million in Q3 2025.

  • For Q3 2025, Assets Average rose 4.54% year-over-year to $30.1 million; the TTM value through Sep 2025 reached $30.1 million, up 4.54%, while the annual FY2024 figure was $27.3 million, 7.76% down from the prior year.
  • Assets Average reached $30.1 million in Q3 2025 per NWBO's latest filing, up from $28.5 million in the prior quarter.
  • Across five years, Assets Average topped out at $35.4 million in Q1 2022 and bottomed at $27.1 million in Q1 2025.
  • Average Assets Average over 5 years is $30.1 million, with a median of $29.7 million recorded in 2023.
  • Peak YoY movement for Assets Average: skyrocketed 229.66% in 2021, then fell 12.09% in 2024.
  • A 5-year view of Assets Average shows it stood at $34.2 million in 2021, then fell by 8.72% to $31.2 million in 2022, then fell by 4.91% to $29.7 million in 2023, then dropped by 5.57% to $28.0 million in 2024, then grew by 7.33% to $30.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Assets Average were $30.1 million in Q3 2025, $28.5 million in Q2 2025, and $27.1 million in Q1 2025.